Clicky

Silence Therapeutics Plc(SLN) News

Date Title
Jul 18 European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
Jul 17 European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
Jul 16 European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Jul 15 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
Jun 27 European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
Jun 24 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Jun 17 European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Aug 27 Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
Jun 27 Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
Jun 24 Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Jun 20 Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
Feb 28 Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Feb 28 Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
Feb 23 Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
Jan 11 All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Dec 24 This Silence Therapeutics Insider Increased Their Holding In The Last Year
Dec 6 Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
Dec 1 Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
Nov 27 Silence Therapeutics plc's (NASDAQ:SLN) 65% Price Boost Is Out Of Tune With Revenues
Sep 6 Silence Therapeutics to Participate in September Investor Conferences